Why It Matters
American Laboratories Pharma faces a critical opportunity as Congress actively reshores pharmaceutical manufacturing with bipartisan momentum. The company must navigate a crowded legislative landscape to secure federal contracts and protected markets. The core challenge is straightforward—the U.S. relies on China for roughly 80% of generic drug ingredients, creating persistent shortages and national security concerns.
Multiple bills moving through Congress, including the RAPID Reserve Act and ABC Safe Drug Act, would create contracting opportunities and restrict foreign sourcing. For American Laboratories Pharma, lobbying success means positioning itself as an essential domestic supplier eligible for the $500 million in proposed federal contracts and tax incentives. The company’s decision to hire First Principles Strategies LLC—a firm with pharmaceutical supply chain expertise—suggests it’s betting heavily on influencing which domestic manufacturers win preferential treatment.
By the Numbers
American Laboratories Pharma LLC is a first-time federal lobbying entrant, spending $117,500 total in 2025 through two separate firms.
The company initially engaged Old North Strategies LLC, spending $37,500 on healthcare supply chain issues before terminating that relationship in November. It then pivoted to First Principles Strategies LLC, paying $80,000 for Q3 work on domestic manufacturing reforms.
The shift suggests a recalibrated strategy favoring specialized expertise. First Principles brings pharmaceutical policy experience, having represented Exela Pharma Sciences LLC since 2020 on supply chain security and manufacturing policy.
The Agenda
American Laboratories Pharma is lobbying on domestic pharmaceutical manufacturing and supply chain reform. The company, which manufactures enzymes and ingredients for pharmaceuticals and dietary supplements, focuses on "Manufacturing Domestic Supply Reforms" and supply chain issues.
The timing aligns with major congressional push to reshore pharmaceutical production. Key bills advancing include the RAPID Reserve Act, which would fund federal contracts with domestic manufacturers for critical drug reserves, and the ABC Safe Drug Act, which aims to eliminate Chinese-sourced ingredients from federal health programs by 2030. The MMEDS Act offers a 40% tax credit for medical manufacturing in economically distressed zones.
This environment directly benefits domestic ingredient producers like American Laboratories Pharma, which specializes in pancreatin, pepsin, and bile—critical components facing persistent global shortages.
Broader Context
Congress is mobilizing around pharmaceutical reshoring with bipartisan enthusiasm. The U.S. faces persistent shortages affecting 214 drugs, with 84% being generics—precisely American Laboratories Pharma’s market.
China dominates 80% of the global generic API supply chain, prompting lawmakers to frame reshoring as strategic necessity. The Trump administration has streamlined FDA and EPA permitting for domestic pharmaceutical facilities. Congressional leadership, including Senators Peters, Blackburn, Kaine, and Budd, champions domestic production.
Between The Lines
Multiple pieces of legislation are advancing simultaneously. The RAPID Reserve Act proposes $500 million in federal contracts, while the ABC Safe Drug Act would phase out Chinese-sourced ingredients. Senator Dick Durbin is developing dietary supplement listing requirements that could affect ingredient suppliers.
House members launched the American-Made Medicines Caucus to promote onshoring policies, while Senators Gillibrand and Scott sent bipartisan correspondence to FDA demanding investigation into foreign manufacturer oversight.
Competitive Landscape
American Laboratories Pharma faces competition for federal support. First Principles Strategies’ client roster shows active engagement on supply chain issues, representing Exela Pharma Sciences LLC on nearly identical priorities.
In adjacent sectors, the American Feed Industry Association lobbies on ingredient safety, while major manufacturers including Diamond Pet Foods and Mars Inc. engage on ingredient regulation. However, American Laboratories Pharma’s specialization in enzyme and protein ingredients for pharmaceuticals provides distinct positioning.
The Bottom Line
American Laboratories Pharma is entering federal lobbying at a moment of significant policy opportunity. The company’s $80,000 investment with First Principles aligns with bipartisan momentum to reshape U.S. pharmaceutical manufacturing. While persistent drug shortages and national security concerns have created political will for reshoring, substantial barriers remain around costs, labor availability, and regulatory timelines. The legislative environment remains fluid and dependent on broader economic and geopolitical conditions.
Access the Legis1 platform for comprehensive political news, data, and insights.